Pharmacological Modulation of Belief Salience
NCT03754062 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2019-10-10
Summary
To provide an initial test of the hypothesis that dopamine mediates the motivational salience of stimuli beyond simple stimulus-reinforcement associations, the researchers propose to undertake a study of the modulation of a) levels of agreement or disagreement with; b) the perceived self- relevance; and c) the perceived interest of propositions expressing beliefs and values in healthy male volunteers using Ii) a dopamine antagonist (the D2-blocker haloperidol), and (ii) a dopamine precursor L-Dopa to increase CNS dopamine transmission.
The researchers will also administer the Salience Attribution Task (SAT) which will allow researchers to assess reward-learning processing of simple stimuli using a reaction-time game. This task was utilised by Roiser et al in order to explore whether delusions in medicated patients with schizophrenia were related to impairments in associative learning. The authors hypothesised that associative learning was influenced by D2 receptor blockade. The researchers extend this approach to examine the effect of dopamine modulation on the SAT as a measure of associative learning, a basic neuropsychological process that may be involved in the attribution of salience to beliefs.
Finally, the researchers will ask participants to perform a within-subjects dictator game to understand the influence of dopaminergic manipulation of the live attribution of harm intention to partners. The task has been previously validated online. Participants will play against 3 partners in a random order in each drug condition. Each partner will play the participant for 6 trials. One partner will always be fair, one will always be unfair, and one will be 50% unfair. We aim to understand whether potentiating dopamine has an additive effect on the harm intention attributions toward partners, regardless of the behaviour of the partner.
Conditions
- Haloperidol
- Placebo
- L-DOPA
Interventions
- DRUG
-
Placebo - Cap
Administration of Placebo by pill.
- DRUG
-
L-dopa
Administration of L-dopa by pill.
- DRUG
-
Haloperidol
Administration of Haloperidol by pill.
Sponsors & Collaborators
- collaborator OTHER_GOV
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-06-01
- Primary Completion
- 2019-09-01
- Completion
- 2019-09-01
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study of the Effectiveness of Electronic Interventions on the Standardized Prescription Benzodiazepines and Z-drugs
NCT03724669 ·Status: COMPLETED ·Phase: NA
-
The Association Between Physical Sensations and Thinking Styles
NCT03233542 ·Status: COMPLETED ·Phase: NA
-
Longterm Effects of Expectations on Mood
NCT03607214 ·Status: COMPLETED ·Phase: NA
-
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
NCT00542685 ·Status: COMPLETED ·Phase: PHASE3
-
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
NCT02153944 ·Status: COMPLETED ·Phase: PHASE4
-
Examining the Usage of Dopamine Blockers in OCD Patients
NCT00496925 ·Status: COMPLETED
-
Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
NCT00632229 ·Status: COMPLETED ·Phase: PHASE2
-
Locating Biomarkers in OCD Through Behavioral Tasks
NCT03313622 ·Status: NOT_YET_RECRUITING
-
A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder
NCT00470483 ·Status: COMPLETED ·Phase: PHASE1
-
Statistical Learning as a Predictor of Attention Bias Modification Outcome
NCT03424967 ·Status: COMPLETED ·Phase: NA
-
Prefrontal Oscillations in Social Anxiety Disorder (POSAD)
NCT03821779 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Affect-regulatory Characteristics of Deceptive Placebos
NCT05372744 ·Status: COMPLETED ·Phase: NA
-
Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability
NCT00751465 ·Status: COMPLETED ·Phase: NA
-
A Neuropsychological Characterization of Social Feedback Processing in Social Anxiety
NCT03547713 ·Status: COMPLETED ·Phase: NA
-
Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety
NCT06564402 ·Status: RECRUITING ·Phase: NA
-
Piloting MOL Intervention for Neuroleptic Decision Making
NCT03537040 ·Status: COMPLETED ·Phase: NA
-
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
NCT02922166 ·Status: UNKNOWN ·Phase: PHASE1
-
Attentional Bias Modification Treatment in OCD
NCT02014194 ·Status: COMPLETED ·Phase: NA
-
Quetiapine in Specific Phobia
NCT00872716 ·Status: COMPLETED ·Phase: PHASE2
-
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
NCT03033056 ·Status: COMPLETED
-
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
NCT04131829 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
NCT01826786 ·Status: COMPLETED ·Phase: PHASE1
-
Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.
NCT03068429 ·Status: COMPLETED ·Phase: PHASE4
-
Neurobehavioral Investigations of Approach Dynamics in the Ventral Striatum
NCT05422469 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome
NCT00114127 ·Status: COMPLETED ·Phase: PHASE3